Ipsen (IPSEY) has announced the extension of its collaboration and license agreement with Exelixis for the development of Cabometyx (cabozantinib) targeting advanced pancreatic neuroendocrine tumors (pNETs) and advanced extra-pancreatic neuroendocrine tumors (epNETs).
This agreement follows positive results from the CABINET Phase III trial, which was led by the Alliance for Clinical Trials in Oncology and sponsored by the National Cancer Institute (NCI). The trial evaluated Cabometyx versus placebo in patients with advanced pNETs or advanced epNETs whose disease had progressed after prior systemic therapy.
Ipsen also noted its ongoing engagement with regulatory authorities in the European Union and plans to submit a regulatory filing based on the trial data.
